Click-to-release for controlled immune cell activation: tumor-targeted unmasking of an IL12 prodrug
Preprint
- 24 July 2025
- preprint
- Published by American Chemical Society (ACS) in ChemRxiv
Abstract
Objectives. Immunotherapy utilizing immune stimulating cytokines such as IL12 holds great promise for the treatment of cancer. However, clinical use of IL12 is hampered due to severe toxicity following systemic administration. We here present a novel treatment strategy in which IL12 is chemically silenced by conjugation to PEG masks that can be released on demand using a bioorthogonal click reaction, restoring the native cytokine. This “click-to-release” approach is based on the IEDDA pyridazine elimination reaction between a tetrazine and a trans-cyclooctene (TCO). Selective activation in the tumor microenvironment is achieved by pretargeting one component of this reaction to the tumor, triggering local activation of the masked IL12 once it is given in a secondary i.v. injection. Methods. IL12 masking and unmasking was evaluated in vitro with PAGE and HEK-Blue reporter cells and ex vivo with ELISA. Biodistribution in mice was evaluated with I-125 radiolabeling and biotin-click histochemistry. Results. Several designs were evaluated and optimized in vitro resulting in an IL12-TCO-PEG construct that exhibited superior masking- and subsequent re-activation upon reaction with a tetrazine bound to a TAG-72-targeted diabody. In tumor-bearing mice, we demonstrated that this diabody-tetrazine could efficiently pre-localize tetrazine in the tumor. Administration of IL12-TCO-PEG 24 hrs later afforded efficient and selective unmasking in tumors, but not in blood. Conclusions. These results demonstrate proof of principle of the click-cleavable IL12 prodrug approach and showcase the versatility of the click-to-release reaction.Keywords
All Related Versions
This publication has 37 references indexed in Scilit:
- Toward Realization of Bioorthogonal Chemistry in the ClinicTopics in Current Chemistry, 2025
- Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapyJournal of Controlled Release, 2022
- Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cellsCell, 2021
- Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylationToxicology and Applied Pharmacology, 2020
- Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic TherapiesCancer Cell, 2017
- PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved DrugsJournal of Pharmaceutical Sciences, 2016
- Construction, expression, and function of 6B11ScFv–mIL-12, a fusion protein that attacks human ovarian carcinomaMedical Oncology, 2015
- Interleukin 12: still a promising candidate for tumor immunotherapy?Cancer Immunology, Immunotherapy, 2014
- Click to Release: Instantaneous Doxorubicin Elimination upon Tetrazine LigationAngewandte Chemie International Edition, 2013
- huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor modelsCancer Immunology, Immunotherapy, 2006